Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17494254 | 1.00 | KCNH2 (0.53) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17494427 | 1.00 | KCNH2 (0.53) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17494265 | 0.93 | KCNH2 (0.45) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17494262 | 0.93 | KCNH2 (0.45) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17494388 | 0.92 | SCN5A (0.59) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17494260 | 0.92 | SCN5A (0.59) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17494258 | 0.92 | SCN5A (0.59) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19194881 | 0.88 | KCNH2 (0.56) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19195317 | 0.87 | KCNH2 (0.55) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17494313 | 0.87 | KCNH2 (0.53) | KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160726-B2 | Quinolone derivatives as antibacterials | NOVARTIS AG (CH) | 2018-12-25 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| EP-3177593-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020836-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | TOP1, NQO2, TOP2A | KCNH2 3467/4885SCN5A 1288/4885CYP1A2 139/4885 |
| US-10160726-B2 | Quinolone derivatives as antibacterials | TOP1, NQO2, TOP2A | KCNH2 3467/4885SCN5A 1288/4885CYP1A2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.